Article

A plasma-based DNA test for quantification of disease burden in acute myeloid leukemia patients undergoing bone marrow transplantation

2026-02-11

Abstract excerpt

<h4>ABSTRACT</h4> Allogeneic hematopoietic cell transplantation is the only curative option for many patients with acute myeloid leukemia (AML). In the current study, we designed and implemented a personalized assay, called v96, incorporating up to 96 mutations in 30 AML patients undergoing transplantation. The assay was performed on DNA derived in cells from the bone marrow as well as in cell-free plasma. All 30...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f1f84342-0594-5cfc-8fb0-13525b183400
DOI: 10.64898/2026.02.10.26345949

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A plasma-based DNA test for quantification of disease burden in acute myeloid leukemia patients undergoing bone marrow transplantationDOI 10.64898/2026.02.10.26345949Read

A plasma-based DNA test for quantification of disease burden in acute myeloid leukemia patients undergoing bone marrow transplantation.Semantic proximity Read

Cell-free DNA profiling informs all major complications of hematopoietic cell transplantationSemantic proximity Read

Cell-free DNA Profiling Informs Major Complications of Hematopoietic Cell TransplantationSemantic proximity Read

Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic TransplantationSemantic proximity Read

Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemiaSemantic proximity Read

Personalized Circulating Tumor DNA (ctDNA) Profiling Enables Superior and Universal Measurable Residual Disease (MRD) Detection in Acute Myeloid Leukemia (AML)Semantic proximity Read

Tracking Rare Single Donor and Recipient Immune and Leukemia Cells after Allogeneic Hematopoietic Cell Transplantation Using Mitochondrial DNA Mutations.Semantic proximity Read

Next-Generation Sequencing-Assisted DNA-Based Digital PCR for a Personalized Approach to the Detection and Quantification of Residual Disease in Chronic Myeloid Leukemia PatientsSemantic proximity Read

Cell-free DNA measurable residual disease as a predictor of postallogeneic hematopoietic cell transplant outcomes.Semantic proximity Read

Significance of Measurable Residual Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid LeukemiaSemantic proximity Read

Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNASemantic proximity Read

Measurable residual disease in chronic myeloid leukemiaSemantic proximity Read